(Q36675454)

15 August 2017

1 reference

title

A review of vaccine clinical trials for non-small cell lung cancer (English)

1 reference

15 August 2017

Nemunaitis J

1

1 reference

15 August 2017

Nemunaitis J

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

89-102

1 reference

Revisions in the International System for Staging Lung Cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Vaccines in cancer: GVAX, a GM-CSF gene vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

The development of immunotherapies for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Non-small-cell lung cancer vaccine therapy: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Models of T cell anergy: is there a common molecular mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Anergic T cells as suppressor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Modulation of T-cell function by gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Expression of the highly conserved RNA binding protein KOC in embryogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Epidermal growth factor receptor inhibition and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

T cell defined tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

GM-CSF-based cellular vaccines: a review of the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Genetically engineered tumor cell vaccine in a head and neck cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

The TGF-beta family of growth and differentiation factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Transforming growth factor-beta in disease: the dark side of tissue repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Immunotherapy of cancer with dendritic-cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Dendritic cell vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Clinical applications of dendritic cell vaccination in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Autologous dendritic cell vaccines for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

B lymphocytes secrete antigen-presenting vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Therapeutic vaccines against melanoma and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

Deactivation of macrophages by transforming growth factor-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.89

21 January 2018

Identifiers

DOI

10.1517/14712598.7.1.89

1 reference

15 August 2017

1 reference